0001104659-21-107740.txt : 20210819 0001104659-21-107740.hdr.sgml : 20210819 20210819161239 ACCESSION NUMBER: 0001104659-21-107740 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210819 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210819 DATE AS OF CHANGE: 20210819 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Marker Therapeutics, Inc. CENTRAL INDEX KEY: 0001094038 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880277072 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37939 FILM NUMBER: 211190226 BUSINESS ADDRESS: STREET 1: 3200 SOUTHWEST FREEWAY STREET 2: SUITE 2500 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: (713) 400-6400 MAIL ADDRESS: STREET 1: 3200 SOUTHWEST FREEWAY STREET 2: SUITE 2500 CITY: HOUSTON STATE: TX ZIP: 77027 FORMER COMPANY: FORMER CONFORMED NAME: TAPIMMUNE INC. DATE OF NAME CHANGE: 20170629 FORMER COMPANY: FORMER CONFORMED NAME: TAPIMMUNE INC DATE OF NAME CHANGE: 20070628 FORMER COMPANY: FORMER CONFORMED NAME: GENEMAX CORP DATE OF NAME CHANGE: 20020718 8-K 1 tm2124472d4_8k.htm FORM 8-K
0001094038 false 0001094038 2021-08-19 2021-08-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

August 19, 2021

Date of Report (Date of earliest event reported)

 

MARKER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-37939 45-4497941
(State or other jurisdiction of
incorporation)		 (Commission File Number) (IRS Employer Identification No.)

 

3200 Southwest Freeway

Suite 2500

Houston, Texas

   77027
(Address of principal executive offices)   (Zip Code)

 

(713) 400-6400

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange on which registered
Common Stock, par value $0.001 per share   MRKR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 7.01Regulation FD Disclosure.

 

On August 19, 2021, Marker Therapeutics, Inc. (the “Company”) issued a press release entitled “Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas.” A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

 

The information in this Item 7.01 of this Current Report on 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press release, dated August 19, 2021
104   Inline XBRL for the cover page of this Current Report on Form 8-K

 

 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Marker Therapeutics, Inc.
     
Dated: August 19, 2021 By: /s/ Anthony Kim
    Anthony Kim
    Chief Financial Officer

 

 

 

 EX-99.1 2 tm2124472d4_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas

 

Houston, TX—August 19, 2021—Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the Company’s Phase 2 clinical trial of its lead MultiTAA-specific T cell product MT-401.

 

The CPRIT award is intended to support the adjuvant arm of the Company’s Phase 2 clinical trial evaluating MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia (AML) following a hematopoietic stem cell transplant. The primary objectives of the adjuvant arm of the trial are to evaluate relapse-free survival after MT-401 treatment when compared with a randomized control group.

 

"We are honored to have been approved by CPRIT for this award which provides additional capital to support the clinical development of MT-401 and external validation of our technology from experts in the field who conducted business and scientific diligence on behalf of CPRIT,” said Peter L. Hoang, President & CEO of Marker Therapeutics. “Our MultiTAA-specific T cell therapy approach has shown encouraging results in post-transplant AML in clinical studies, and we are pleased to advance the clinical development of MT-401 in our Phase 2 trial.”

 

About the Cancer Prevention and Research Institute of Texas

 

To date, CPRIT has awarded $2.9 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs. CPRIT has recruited 237 distinguished researchers, supported the establishment, expansion or relocation of 43 companies to Texas and generated over $5.7 billion in additional public and private investment. CPRIT funding has advanced scientific and clinical knowledge and provided 7.4 million life-saving cancer prevention and early detection services reaching Texans from all 254 counties. On November 5, 2019, Texas voters overwhelmingly approved a constitutional amendment to provide an additional $3 billion to CPRIT for a total $6 billion investment in cancer research and prevention.

 

About Marker's Phase 2 AML Post-Transplant Study

 

The multicenter Phase 2 AML study is evaluating the clinical efficacy of MT-401 in patients with AML following an allogeneic stem-cell transplant in both the adjuvant and active disease setting. In the adjuvant setting, approximately 120 patients will be randomized 1:1 to either MT-401 at 90 days post-transplant versus standard-of-care observation, while approximately 40 patients with active disease will receive MT-401 as part of the single-arm group.

 

 

 

 

The primary objectives of the trial are to evaluate relapse-free survival in the adjuvant group and determine the complete remission rate and duration of complete remission in active disease patients. Additional objectives include, for the adjuvant group, overall survival and graft-versus-host disease relapse-free survival while additional objectives for the active disease group include overall response rate, duration of response, progression-free survival and overall survival.

 

In April 2020, the FDA granted Orphan Drug designation to MT-401 for the treatment of patients with AML following allogeneic stem cell transplant.

 

About Marker Therapeutics, Inc.

 

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

 

To receive future press releases via email, please visit:

https://www.markertherapeutics.com/email-alerts.

 

Forward-Looking Statements

 

This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of our clinical trials, including the Phase 2 trial of MT-401;and our use of our cash and cash equivalents, future operating expenses and capital expenditure requirements. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

 

2

 

 

Contacts

 

Investors

Solebury Trout

Xuan Yang

(646) 378-2975

xyang@soleburytrout.com

 

Media

Solebury Trout

Amy Bonanno

(914) 450-0349

abonanno@soleburytrout.com

 

##

3

 

 EX-101.SCH 3 mrkr-20210819.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mrkr-20210819_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mrkr-20210819_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2124472d4_ex99-1img001.jpg GRAPHIC begin 644 tm2124472d4_ex99-1img001.jpg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tm2124472d4_8k_htm.xml IDEA: XBRL DOCUMENT 0001094038 2021-08-19 2021-08-19 iso4217:USD shares iso4217:USD shares 0001094038 false 8-K 2021-08-19 MARKER THERAPEUTICS, INC. DE 001-37939 45-4497941 3200 Southwest Freeway Suite 2500 Houston TX 77027 713 400-6400 false false false false Common Stock, par value $0.001 per share MRKR NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Aug. 19, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 19, 2021
Entity File Number 001-37939
Entity Registrant Name MARKER THERAPEUTICS, INC.
Entity Central Index Key 0001094038
Entity Tax Identification Number 45-4497941
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3200 Southwest Freeway
Entity Address, Address Line Two Suite 2500
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77027
City Area Code 713
Local Phone Number 400-6400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol MRKR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( )*!$U,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "2@1-3L31ZHNX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)VE!-'1[43PI""XHWD(RNQMLFI",M/OVIG&WB^@#>,S,GV^^ M@>ETD-I'?(X^8"2+Z6IVPYBD#AMV( H2(.D#.I7JG!AS<^>C4Y2?<0]!Z0^U M1V@XOP:'I(PB!0NP"BN1]9W14D=4Y.,);_2*#Y]Q*#"C 0=T.%("40M@_3(Q M'.>A@PM@@1%&E[X+:%9BJ?Z)+1U@I^2<[)J:IJF>VI++.PAX>WI\*>M6=DRD M1HWY5[*2C@$W[#SYM;V[WSZPON&-J/A-)6ZW#9>BD6W[OKC^\+L(.V_LSOYC MX[-@W\&ON^B_ %!+ P04 " "2@1-3F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M )*!$U/#MY6L400 -D0 8 >&PO=V]R:W-H965T&UL MG9A=;^I&$(:O3W_%"O6BE4C\@1/"$4$BA#0H)SD4)T+>MM3'99\?1T9JE5%_* MC GX9BE52@V.[[K634BY:@WYQ;:H&?9F;A LV543G:4K5 M]HXEVKHH*_DABA[-ZC9 M@V*I133 <6&K$AH%WW*(,X.1?&.J[QB0LA><:!]VMPOS3X0-\]4E\7IMXKN^ M]^]P!PA*#+_$\ N]#H9!_APNM%%0J+\0R4XIV2DD@Q.2]S+*H7T,F6\S5K=" M//SFX@F!"$J( %49 D%<4#PD=%5'@<%F2QYXPLA+GB[J^Q'7<%WOHM/M=7H(3[?D MZ9[#,V,K;KL1DO9"T]I,X3K/P]G3>$;FC^/9<#K^-I^,PC:9O(PN$<:;DO'F M',81E%31A$Q$S-[)$]O64>)*+J3.[05NYP;!ZI58O7.PYO2=3&)@XTL>T<)] M3Q<65PRN+H*@U^T%6*=Y;N5V[CF $Q%)E4E5L+5):.!1(%*1D_I7K8H35(/!P*_](.+)G4.VYW(A:.ESN4=JQ M+#"T:CQXN+]_1"L[<:KD&Q=1?:UQS?GO&%HU,3S] MN [P9J\&@X?[^7?%C6$"$I.FN=C;KZZEPH6:MAY>-10\W,-#F?"(&RY6Y!G: M6W&:U/+@*DT\?C4$?-RFIXI=1) >!L_7;H<(FS38?GY=+NOKUZ#72%8YOX_; M]'_()EKG0-8(B,LV AYMTW%GGG,#NS2Y))[_T^)G$K(HAWZKW78T*-G^A'U! M:&3TVB895>2-)CDC/[J7L",A&2Q7KZE"L:L)X..6/56QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+3 M8JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A M8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72L MJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GT MA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WAT MUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:I MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 M]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NX MZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8; M9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%' MGL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G M)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 M" "2@1-3EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q="> M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C] M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA< MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X M4$L#!!0 ( )*!$U.JQ"(6,P$ "(" / >&PO=V]R:V)O;VLN>&UL MC5'1;L(P#/R5*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I3< MV;K<7187XM.!Z)1\>1=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[ M=)IEL]1;#&:Y&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C M%B/%*0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@ MA1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146 ML*:B]1!DZ)'!=09#K+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E M5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04 M" "2@1-3)!Z;HJT #X 0 &@ 'AL+U]R96QS+W=O[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++ M3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$ M% @ DH$34V60>9(9 0 SP, !, !;0V]N=&5N=%]4>7!E&UL MK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QX MWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6# M4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$ MJ+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L: M!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U5 M9"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\ MUDX:?^:+X3]>?P%02P$"% ,4 " "2@1-3!T%-8H$ "Q $ M @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( )*!$U.Q M-'JB[@ "L" 1 " :\ !D;V-0&UL4$L! A0#% @ DH$34\.WE:Q1! MV1 !@ ("!#0@ 'AL+W=O7!E&UL 64$L%!@ ) D /@( .@3 $! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tapimmune.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2124472d4_8k.htm mrkr-20210819.xsd mrkr-20210819_lab.xml mrkr-20210819_pre.xml tm2124472d4_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2124472d4_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2124472d4_8k.htm" ] }, "labelLink": { "local": [ "mrkr-20210819_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "mrkr-20210819_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "mrkr-20210819.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mrkr", "nsuri": "http://tapimmune.com/20210819", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "b", "p", "body", "html" ], "baseRef": "tm2124472d4_8k.htm", "contextRef": "From2021-08-19to2021-08-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://tapimmune.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "b", "p", "body", "html" ], "baseRef": "tm2124472d4_8k.htm", "contextRef": "From2021-08-19to2021-08-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-107740-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-107740-xbrl.zip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